Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium–Glucose Co-transporter-2 Inhibitors

The number of people living with type 2 diabetes (T2D) and its complications worldwide is increasing at an alarming rate. Fortunately, our understanding of the benefits of glucose-lowering agents from the sodium–glucose co-transporter-2 (SGLT2) inhibitor and glucagon-like peptide-1 (GLP-1) receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Neumiller, Joshua J, Lienhard, Fredrick J, Alicic, Radica Z, Tuttle, Katherine R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2022
Materias:
Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835817/
https://www.ncbi.nlm.nih.gov/pubmed/36694888
http://dx.doi.org/10.17925/EE.2022.18.2.106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835817/
https://www.ncbi.nlm.nih.gov/pubmed/36694888
http://dx.doi.org/10.17925/EE.2022.18.2.106

Ejemplares similares